Clinical Trials Search

Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Allergan
Details (Identifier #): NCT02574637
Title: DC5170C00002, A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy
Department: Gastroenterology
Diagnosis: Gastrointestinal - Crohn's
Principal Investigator: McDonald M.D., Thomas
Sponsor: Eli Lilly
Details (Identifier #): NCT02891226
Title: 16T-MC-AMAG, A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Seres
Details (Identifier #): NCT03183128
Title: A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults (SERES-012)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator: Georgetson MD, FACG, Michael
Sponsor: Seres
Details (Identifier #): NCT03183141
Title: ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI)
Department: Gastroenterology
Diagnosis: Gastrointestinal - Liver
Principal Investigator: McDonald M.D., Thomas
Sponsor: Gilead Sciences
Details (Identifier #): NCT03053050
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis